BTMD vs NAGE
biote Corp. and Niagen Bioscience, Inc., side by side — 5 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BTMD | NAGE |
|---|---|---|
| Revenue | $192.2M | $129.4M |
| Net income | $27.0M | $17.4M |
| Gross margin | 71.5% | 64.3% |
| Net margin | 16.4% | 13.4% |
| Return on equity | — | 28.3% |
| Diluted EPS | $0.74 | $0.20 |
| Dividend / share | — | — |
| Payout ratio | 6.4% | — |
| Free cash flow | $30.2M | — |
| Equity | $-58.5M | $76.5M |
| Net debt / equity | — | — |
| Current ratio | 1.22× | 4.86× |
| Revenue CAGR 5y | — | 16.9% |
| Profit CAGR 5y | — | — |
BTMD bills 1.5× the revenue of NAGE, and keeps more of each dollar of revenue as profit (16.4% against 13.4%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
5 years side by side
| Fiscal year | BTMD | NAGE |
|---|---|---|
| FY2025 | $192.2M | $129.4M |
| FY2024 | $197.2M | $99.6M |
| FY2023 | $185.4M | $83.6M |
| FY2022 | $165.0M | $72.0M |
| FY2021 | $139.4M | $67.4M |
Net income by year
Bottom line
| Fiscal year | BTMD | NAGE |
|---|---|---|
| FY2025 | $27.0M | $17.4M |
| FY2024 | $3.2M | $8.6M |
| FY2023 | $3.3M | $-4.9M |
| FY2022 | $-969,000 | $-16.5M |
| FY2021 | $32.6M | $-27.1M |
More in this industry